Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET
Company Participants
Jennifer Good - President and CEO
Lisa Delfini - Chief Financial Officer
David Clark - Chief Medical Officer
Conference Call Participants
Thomas Smith - Leerink Partners
Leland Gershell - Oppenheimer
Mayank Mamtani - B. Riley Securities
Brandon Folkes - Rodman & Renshaw
John Gionco - Needham & Company
Debanjana Chatterjee - JonesTrading
Operator
Good afternoon. And welcome to the Trevi Therapeutics Second Quarter 2024 Earnings Conference Call. At this time, all participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
Various remarks that management makes during this conference call about the company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the Safe Harbor act, Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factor section of the company’s most recent quarterly report on Form 10-Q, which the company filed with the SEC this afternoon.
In addition, any forward-looking statements represent the company’s views only as of today and should not be relied upon as representing the company’s views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its views change.
I would now like to turn the conference over to Jennifer Good, Trevi’s President and CEO. Please go ahead.
Jennifer Good
Good afternoon. And thank you for joining us for our second quarter 2024 earnings call and business update. Joining me today on this call are my colleagues Lisa Delfini, Trevi’s Chief Financial Officer; and Dr. David Clark, Trevi’s Chief Medical Officer. I will give an update on the progress in our clinical trials and Lisa will give a brief financial update. Then the three of us are happy to answer any questions that you may have.
This has been a fun but busy quarter at Trevi as we continue to execute against our clinical development plans for both chronic coughs and idiopathic pulmonary fibrosis, or IPF, as well as refractory chronic cough or RCC. We have a number of data readouts expected by year-end and are hoping to build on the strong efficacy data we saw in our Phase 2a trial in IPF chronic cough.